BEACON treatment with cetuximab every second week - cetuximab given every second week with encorafenib in prior treated patients with spred bowel cancer with a specific (BRAF) mutation. A drug trial.
收藏NIAID Data Ecosystem2026-03-12 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2540537
下载链接
链接失效反馈官方服务：
资源简介：
Primary objectives: The purpose of this study is to evaluate the efficacy and tolerability of cetuximab every second week together with encorafenib in patients with pre-treated, metastatic BRAF-mutated colorectal adenocarcinoma.Primary objective is 2 months Progression Free Survival (PFS) rate.
Primary endpoints: 2 months PFS rate
创建时间：
2020-11-15
